Zobrazeno 1 - 10
of 18
pro vyhledávání: '"Anne-Sophie Govaerts"'
Autor:
Godefridus J. Peters, Anne-Sophie Govaerts, Hans R. Hendriks, for EORTC Pharmacology and Molecular Mechanism Group
Publikováno v:
ADMET and DMPK, Vol 6, Iss 1, Pp 4-14 (2018)
Drug development consists of many sequential and parallel steps; failure in one of the steps can lead to discontinuation of the process. The process is time-consuming and very expensive, especially the clinical phase. In order to enhance cancer drug
Externí odkaz:
https://doaj.org/article/20d0c7f90ac847cda41fa113cde4fb9d
Autor:
Jean-Jacques Stelmes, Vincent Gregoire, Vincent Vander Poorten, Wojciech Golusiñski, Mateusz Szewczyk, Terry Jones, Mohssen Ansarin, Martina A. Broglie, Roland Giger, Jens Peter Klussmann, Mererid Evans, Jean Bourhis, C. René Leemans, Giuseppe Spriano, Andreas Dietz, Keith Hunter, Frank Zimmermann, Ingeborg Tinhofer, Joanne M. Patterson, Silvana Quaglini, Anne-Sophie Govaerts, Catherine Fortpied, Christian Simon
Publikováno v:
Frontiers in Oncology, Vol 9 (2019)
Dysphagia represents one of the most serious adverse events after curative-intent treatments with a tremendous impact on quality of life in patients with head and neck cancers. Novel surgical and radiation therapy techniques have been developed to be
Externí odkaz:
https://doaj.org/article/6ea186b7a8a2407ea399e048ac39749f
Autor:
Jenny F. Seligmann, Thibaud Kossler, Murielle Mauer, Serge Evrard, Elske C. Gootjes, Jacob Freedman, Matthias Guckenberger, Anne-Sophie Govaerts, Anne Giraut, Jens Ricke, Gunnar Folprecht, Dirk Arnold, Ramesh Vishwakarma, Michel Ducreux, Theo JM Ruers
Publikováno v:
Journal of Clinical Oncology. 41:141-141
141 Background: Treatment for patients (pts) with metastatic colorectal cancer (mCRC) with unresectable liver metastases (mets) is usually chemotherapy (CT) +/- local ablative treatments. Immunotherapy (IO) effect is disappointing in mCRC with pMMR s
Autor:
Jean-Luc Canon, Marie Christine Kaminsky, Sylvie Zanetta, Inge Tinhofer, Edith Borcoman, Sylvie Rottey, Caroline Even, Esma Saada-Bouzid, Anthony Kong, Philip R. Debruyne, Maureen Vanlancker, Lisa Licitra, Tiana Raveloarivahy, Rachel Galot, Catherine Fortpied, Marie Morfouace, Pol Specenier, Anemie Rutten, Anne Sophie Govaerts, Lieve Dirix, Stéphanie Henry, Joël Guigay, Amaury Daste, Christophe Le Tourneau, Jean-Pascal Machiels
Publikováno v:
European Journal of Cancer
European Journal of Cancer, Elsevier, 2021, 158, pp.17-26. ⟨10.1016/j.ejca.2021.09.003⟩
European journal of cancer
European journal of cancer, Vol. 158, p. 17-26 (2021)
European Journal of Cancer, Elsevier, 2021, 158, pp.17-26. ⟨10.1016/j.ejca.2021.09.003⟩
European journal of cancer
European journal of cancer, Vol. 158, p. 17-26 (2021)
Purpose: Monalizumab is a monoclonal antibody targeting the inhibitory natural killer group 2A (NKG2A) receptor localised on natural killer (NK) and T cells. Its ligand, the human leukocyte antigen E (HLA-E), is overexpressed in squamous cell carcino
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::743c7135adc8a0cc75429cd3b704253f
https://hal.archives-ouvertes.fr/hal-03434925
https://hal.archives-ouvertes.fr/hal-03434925
Autor:
Anne-Sophie Govaerts, Godefridus J. Peters, Sally Burtles, H.R. Hendriks, Andrew D. Westwell, Iduna Fichtner
Publikováno v:
Hendriks, H R, Govaerts, A-S, Fichtner, I, Burtles, S, Westwell, A D & Peters, G J 2017, ' Pharmacologically directed strategies in academic anticancer drug discovery based on the European NCI compounds initiative ', British Journal of Cancer, vol. 117, no. 2, pp. 195-202 . https://doi.org/10.1038/bjc.2017.167
British Journal of Cancer
British Journal of Cancer, 117(2), 195-202. Nature Publishing Group
British Journal of Cancer
British Journal of Cancer, 117(2), 195-202. Nature Publishing Group
BACKGROUND: The European NCI compounds programme, a joint initiative of the EORTC Research Branch, Cancer Research Campaign and the US National Cancer Institute, was initiated in 1993. The objective was to help the NCI in reducing the backlog of in v
Autor:
Ahmad Awada, Christophe Le Tourneau, Bojana Milojkovic Kerklaan, Anne-Sophie Govaerts, Hilde Rosing, Véronique Diéras, Alwin D. R. Huitema, Jos H. Beijnen, Marja Mergui-Roelvink, Martine Piccart-Gebhart, Jan H.M. Schellens, Sandrine Marreaud
Publikováno v:
Cancer Chemotherapy and Pharmacology. 71:53-62
This phase I study was performed to determine the maximum tolerated dose (MTD), dose-limiting toxicities (DLT), safety profile, recommended dose for phase II studies, the pharmacokinetics, and antitumor activity of the combination of lonafarnib (farn
Autor:
Christophe Le Tourneau, Esma Saada-Bouzid, Catherine Fortpied, Carmela Caballero, Lisa Licitra, Jean-François Laes, Joël Guigay, Jean-Pascal Machiels, Jean-Luc Re Canon, Stéphanie Henry, Rachel Galot, Anne-Sophie Govaerts, Anthony Hee Kong, Tiana Raveloarivahy, Dominiek Staelens, Inge Tinhofer
Publikováno v:
Journal of Clinical Oncology. 36:TPS6095-TPS6095
TPS6095Background: The treatment of R/M SCCHN includes platinum-based chemotherapy, cetuximab, and anti-PD-1 compounds. Some genetic alterations have been identified, making SCCHN attractive for mo...
Autor:
Philippe, Maingon, Anne-Sophie, Govaerts, Sofia, Rivera, Conchita, Vens, Emad, Shash, Vincent, Grégoire
Publikováno v:
Chinese clinical oncology. 3(2)
Combined modality treatment can be used to improve control of the local disease at the expense of increased toxicity. Several randomized trials have demonstrated that this combined modality therapy is better than radiotherapy alone or chemotherapy al
Autor:
Thierry Guillaume, Michel Symann, Anne-Sophie Govaerts, Babak Bayat, Robert G. Hawley, Marc André, Teresa S. Hawley, Anne Marie Feyens, A Z C Fong
Publikováno v:
Cancer Gene Therapy. 6:447-455
The transfer of genes encoding cytokines into tumor cells has emerged as a new strategy to increase in vivo host reactivity to a variety of tumors. Because gene transfer into tumor cells cannot be easily applied in the clinical setting, we have devel
Autor:
Sandrine Marreaud, Antonio Lambiase, Cornelis J. A. Punt, Arend Heerschap, Johanna N. H. Timmer-Bonte, Claudio Bordignon, Jan Bogaerts, Hanneke W. M. van Laarhoven, Walter Fiedler, Anne-Sophie Govaerts, Jack J.A. van Asten, Carla M.L. van Herpen, Peter Lasch, Ingrid M.E. Desar, Denis Lacombe
Publikováno v:
Clinical Cancer Research, 16, 1315-23
Clinical Cancer Research, 16, 4, pp. 1315-23
Clinical cancer research, 16(4), 1315-1323. American Association for Cancer Research Inc.
Clinical Cancer Research, 16, 4, pp. 1315-23
Clinical cancer research, 16(4), 1315-1323. American Association for Cancer Research Inc.
Purpose: This phase I trial investigating the vascular targeting agent NGR-hTNF aimed to determine the (a) dose-limiting toxicities, (b) maximum tolerated dose (MTD), (c) pharmacokinetics and pharmacodynamics, (d) vascular response by dynamic contras
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::344e73a7b5cedeaec1dd89ac20c351b6
https://doi.org/10.1158/1078-0432.CCR-09-1621
https://doi.org/10.1158/1078-0432.CCR-09-1621